Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Marimed (MRMD) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for Marimed (MRMD) over the last 8 years, with Q3 2025 value amounting to -$0.01.

  • Marimed's EPS (Weighted Average and Diluted) fell 28444.34% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.04, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of -$0.03 for FY2024, which is 2714.1% up from last year.
  • Marimed's EPS (Weighted Average and Diluted) amounted to -$0.01 in Q3 2025, which was down 28444.34% from -$0.0 recorded in Q2 2025.
  • Over the past 5 years, Marimed's EPS (Weighted Average and Diluted) peaked at $0.02 during Q2 2021, and registered a low of -$0.03 during Q4 2023.
  • Over the past 5 years, Marimed's median EPS (Weighted Average and Diluted) value was -$0.0 (recorded in 2024), while the average stood at -$0.0.
  • As far as peak fluctuations go, Marimed's EPS (Weighted Average and Diluted) soared by 53460.12% in 2021, and later plummeted by 32341.8% in 2023.
  • Marimed's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.02 in 2021, then skyrocketed by 172.6% to $0.01 in 2022, then crashed by 323.42% to -$0.03 in 2023, then increased by 24.36% to -$0.02 in 2024, then surged by 52.62% to -$0.01 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.01 for Q3 2025, versus -$0.0 for Q2 2025 and -$0.01 for Q1 2025.